H. Kamlesh¹, E. P. Siva^1,*, P. Bathmanaban², O. D. Makinde³, Dharmendra Tripathi⁴

CMES-Computer Modeling in Engineering & Sciences, Vol.147, No.2, 2026, DOI:10.32604/cmes.2026.081147 - 27 May 2026

Abstract The current study comprehensively investigates Williamson nanofluid flow and transport in an asymmetric porous tapered channel under varying slip conditions, using both analytical and supervised machine learning approaches. This mathematical model integrates thermophoresis, Brownian motion, the Soret and Dufour effects, thermal radiation, and a transverse magnetic field to accurately describe thermosoluble transport phenomena relevant to biomedical contexts. The non-Newtonian Williamson formulation is used to explain how fluids, such as blood, dilute when sheared. Darcy resistance is used to describe porous structures in tissue scaffolds, capillary networks, and dialysis membranes. A perturbation method is used to… More >

Manal Mohammed AL-Tamimi^1,2,*, Siti Norul Huda Sheikh Abdullah^1,*, Mohammad Khatim Hasan¹, Mohammed Azmi Al-Betar^3,4, Maw Shin Sim⁵, Abdulrahman Mohammed AL-Tamimi¹

CMES-Computer Modeling in Engineering & Sciences, Vol.147, No.2, 2026, DOI:10.32604/cmes.2026.079891 - 27 May 2026

Abstract Pan-cancer survival prediction remains a major challenge in personalized oncology due to profound tumor heterogeneity and the complexity of high-dimensional molecular data. Diverse risk profiles across cancer types and noisy, sparse features hinder deep learning models from capturing robust prognostic patterns. Prior pan-cancer studies predominantly focus on multimodal integration or unimodal gene expression analysis, leaving other informative modalities such as Copy Number Variation (CNV) and miRNA expression underexplored. We introduce a new formulation of mixture-of-experts (MoE) survival modeling that recasts expert assignment as a clinically interpretable risk-space decomposition problem. The proposed framework, CoxGuided-SE, constructs an… More >

Abdulrahman Dira Khalaf^1,2,*, Hazlina Hamdan^1,*, Alfian Abdul Halin¹, Noridayu Manshor¹

CMES-Computer Modeling in Engineering & Sciences, Vol.147, No.2, 2026, DOI:10.32604/cmes.2026.075537 - 27 May 2026

Abstract Current automated lesion segmentation methods have limited success, particularly for segmenting small, irregular, or heterogeneous lesions. Moreover, such models require significant computational power, which restricts their scalability and clinical application. To overcome these limitations, a lightweight LANET, which is a layer-attention network based on an encoder–decoder deep-learning architecture, has the explicit goal of increasing the segmentation performance and computational efficiency. The LANET is coupled with three new modules: (i) an attention module that includes a depthwise separable convolution operator to reduce the number of parameters, (ii) a custom attention mechanism, and (iii) an atrous spatial… More > Graphic Abstract

Oncology Research Editorial Office

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.085502 - 21 May 2026

Abstract This article has no abstract. More >

Boqi Zhou^1,2,3, Liping Shen^2,3, Xiaojie Lu^1,2,3,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.079463 - 21 May 2026

Abstract Objectives: Gamma-aminobutyric acid type B (GABAB) receptors are involved in tumor progression, and baclofen exerts broad-spectrum antitumor effects in various cancers. Nevertheless, its specific function and underlying molecular mechanisms in glioma are still largely unclear. This study aimed to evaluate the effects of baclofen on glioma cells and elucidate the associated signaling pathways. Methods: The antitumor effects of baclofen were evaluated in glioma cell lines, and its underlying molecular mechanisms were explored using transcriptome sequencing integrated with Western blotting. The in vivo antitumor efficacy of baclofen was further verified in animal models. Results: In vitro functional assays revealed that… More >

Weixiang Song^1,#, Yanbo Zhang^2,#, Xubo Shen¹, Qin Yu¹, Yujin Liu¹, Yongchun Yu³, Rui Chen^1,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078665 - 21 May 2026

Abstract Objective: Osimertinib can selectively inhibit both epidermal growth factor receptor (EGFR) sensitizing and T790M gatekeeper mutations, and has shown remarkable therapeutic effects in patients with lung adenocarcinoma. However, almost all patients inevitably develop drug resistance. Herein, we sought to clarify the roles of exosomal lncRNA H19 in modulating osimertinib resistance, focusing on the PI3K-PTEN-Akt signaling axis. Methods: Functional assays, including cell viability assay, colony formation, cell apoptosis and xenograft mouse, employed in evaluate the effects of exosomal lncRNA H19 on cell growth and apoptosis. RNA quantitation and western blot were adopted to demonstrate the regulatory roles of… More >

Sebastian A. Wohlfeil^1,2,3,*, Jochen S. Utikal^1,2,3

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078650 - 21 May 2026

Abstract Over the past decade, the therapeutic paradigm of cutaneous melanoma has been transformed strongly, driven by advances in immuno-oncology and precision medicine. Building on the success of immune checkpoint blockade and targeted therapy, new treatment strategies now aim to improve efficacy, overcome resistance, and prolong the durability of responses. Clinical trials on neoadjuvant therapy supporting its clinical use are presented. Furthermore, the latest progress in combinatorial immune checkpoint inhibition such as dual anti-LAG-3 or anti-TIGIT with anti-PD-1 blockade, next-generation bispecific antibody development, mRNA-based vaccines in clinical practice, and intralesional therapies are summarized. Additionally, it outlines More >

Eun-Jeong Jeong^1,2,#, Yeon Soo Kim^2,#, Yujin Lee³, Jae-Sung Ryu⁴, Yung Hyun Choi^5,6, Eunjeong Kim^3,7,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078376 - 21 May 2026

Abstract Objective: The systematic evaluation of expansive genomic databases facilitates the discovery of clinically vital biomarkers. While Sideroflexin 3 (SFXN3) consistently displays elevated expression in head and neck squamous cell carcinoma (HNSCC), its specific pathobiological functions and prognostic value remain insufficiently characterized. This study aims to delineate the clinical and functional significance of SFXN3 in HNSCC. Methods: We interrogated SFXN3 expression patterns, patient survival outcomes, and immune cell infiltration characteristics utilizing multiple independent repositories, including the cancer genome atlas (TCGA) and gene expression omnibus (GEO). The prognostic independence of SFXN3 was verified via multivariate Cox regression. These… More > Graphic Abstract

Dat Quoc Tran¹, Mayu Takeda², Eiji Sugihara², Tetsuya Tsukamoto^2,3, Yasushi Hoshikawa⁴, Yasuyoshi Mizutani¹, Kazuya Shiogama⁵, Naoya Asai⁶, Atsuko Niimi¹, Makoto Sumitomo², Hideyuki Saya², Motoshi Suzuki^1,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078309 - 21 May 2026

Abstract Objectives: Genetic risk models have substantially advanced our understanding of germline pathogenic variants (GPVs) in some malignancies, whereas their clinical significance in lung cancer remains unclear. The present study aimed to better understand potential contribution of GPVs to lung cancer etiology. Methods: A targeted sequencing panel of 143 cancer-related genes was applied to analyze 26 distinct lung adenocarcinoma (LUAD) tumors from 11 patients histopathologically diagnosed with multiple primary lung cancers (MPLC). Tumor classification was performed through integrated evaluation of mutation profiles, and variants shared among tumor lesions were further validated as likely germline or somatic mutations… More >

Wei Jiang¹, You Zheng¹, Zhouhong Jing², Xiangling Yu¹, Huiying Fang^2,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078278 - 21 May 2026

Abstract Background: Breast cancer treatment is often hampered by the immunosuppressive tumor microenvironment (TME). To improve therapeutic efficacy, this study developed a folic acid-chitosan (FA-CS)-modified liposomal formulation co-delivering doxorubicin (DOX) and resiquimod (R848) for combined chemotherapy and immune modulation. Methods: The FA-CS-R848/DOX@Lip liposomes were prepared by rotary evaporation and characterized for morphology, particle size, zeta potential, drug encapsulation efficiency (EE), drug loading (DL) capacity, and drug release profiles. Cellular uptake and cytotoxicity were determined to assess the biological effects of the formulation. Antitumor efficacy and biosafety were assessed in an EO771 tumor-bearing mouse model. The macrophage phenotype,… More >